Clinical Trials Logo

Human Immunodeficiency Virus clinical trials

View clinical trials related to Human Immunodeficiency Virus.

Filter by:

NCT ID: NCT03747003 Active, not recruiting - Clinical trials for Erectile Dysfunction

Gonadal Function in Young to Middle Aged HIV-infected Men

Start date: May 15, 2013
Phase:
Study type: Observational

HIV infection is associated to premature decline of serum testosterone. However, prevalence and biochemical characterization of hypogonadism in HIV-infected men are still to be well defined. HIV-infection is strongly associated to erectile dysfunction in men, but preliminary data suggest that it is poorly associated with serum testosterone in this context.

NCT ID: NCT03742375 Recruiting - Clinical trials for Human Immunodeficiency Virus

Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients

GAIN
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The pathophysiology from anal HPV infection to Anal Intraepithelial Neoplasia is less well understood than cervical HPV infection. In cervical screening programs it is well accepted that the sole presence of a high-risk HPV strain (irrespective of number of viral particles) is sufficient to justify further investigation and treatment. The investigators hypothesize that in anal HPV infection not only the presence but the extent of HPV infection (single genotype viral load) or combination of different HPV genotypes (cumulative viral load) is of importance in determining the risk of anal dysplasia.

NCT ID: NCT03729778 Recruiting - HIV Infections Clinical Trials

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Start date: January 18, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to learn more about both HIV-1 infection and advancing age, alone and in combination, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

NCT ID: NCT03690063 Recruiting - Clinical trials for Human Immunodeficiency Virus

Nice Human Immunodeficiency Virus (HIV) Cohort

Start date: January 1996
Phase:
Study type: Observational [Patient Registry]

Historically, the database on the HIV was organized within the framework of the medico-economic file of the human immunodeficiency (DMI-2), introduced jointly by the Direction of Hospitals (Mission AIDS) and the INSERM at the end of the 80s. Today this database is fed via the computerized medical record NADIS. Most part of the research works on the theme of the HIV take support on this database (DAD, EuroAIDS, Neuradapt).

NCT ID: NCT03666247 Recruiting - Clinical trials for Human Immunodeficiency Virus

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

MMI4MSM RCT
Start date: January 24, 2018
Phase: N/A
Study type: Interventional

The study will evaluate the use and effectiveness of mobile-messaging platforms as a public health strategy for improving sexual health outcome measures among men who have sex with men (MSM) by determining whether exposure to the message-delivery platform results in improvements in participants' self-reported sexual health and prevention behaviors, beliefs and attitudes. The study will enroll men into a randomized controlled trial. Participants randomized to the messaging intervention will have access to a smartphone-based messaging platform for three months while those assigned to the waitlist group will be offered access to the messaging platform after all follow up is complete. Participants will complete surveys at baseline, after the end of the 3 month intervention, and follow up surveys 6 and 9 months after the baseline survey.

NCT ID: NCT03615183 Not yet recruiting - Clinical trials for Human Immunodeficiency Virus

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Start date: December 7, 2018
Phase: Phase 1
Study type: Interventional

This study will evaluate the antiretroviral activity of MK-8527 inHIV-1 infected, ART-naive participants. The primary hypothesis is at that MK-8527 has superior antiretroviral activity compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid ([RNA] at 168 hours postdose.

NCT ID: NCT03583138 Completed - Clinical trials for Human Immunodeficiency Virus

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

Start date: June 23, 2014
Phase: Phase 4
Study type: Interventional

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

NCT ID: NCT03575143 Recruiting - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV

PLWH/OSA
Start date: August 2, 2018
Phase:
Study type: Observational

The investigators seek to understand how the different underlying causes of OSA affect the way people living with HIV (PLWH) experience OSA. The investigators also want to understand how symptoms of obstructive sleep apnea improve with treatment, and if this too, is affected by the underlying cause of OSA in that individual

NCT ID: NCT03561103 Recruiting - Clinical trials for Human Immunodeficiency Virus

Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Client-Centered Representative Payee is a structural intervention that provides financial management support to PLWHA by modifying the implementation of a long-standing policy within the Social Security Administration, in which an organization is authorized to serve as the client's payee. The central hypothesis of this study is that by helping clients to pay rent and other bills on time, housing stability will improve and financial stress will decrease. By reducing the cognitive burden of living with chronic financial stress and frequent threats of housing loss, clients can devote more time and attention to medical appointments and medication adherence. It is further hypothesized that these changes will improve clients' self-efficacy for health behaviors, retention in care, medication adherence, and viral loads. These hypotheses will be tested via the following specific aims: (1) Conduct a randomized controlled trial (n=320) to test the effect of Client-Centered Rep Payee on ART adherence and viral load among PLWHA who are economically disadvantaged and unstably housed. Clinical adherence will be compared through behavioral and biological measures including prescription refill data, self-reported appointment adherence, and viral load for patients receiving the intervention versus those receiving standard of care. (2) Test underlying mechanisms associated with Client-Centered Rep Payee that contribute to changes in medication adherence and viral suppression rates. This will be accomplished via use of quantitative (mediation analysis) and qualitative (semi-structured interview) methods to test hypothesized mediators of medication adherence and viral suppression including financial and housing instability, financial stress, self-efficacy for health behaviors, and retention in care. (3) Assess the cost and cost-effectiveness of the Client-Centered Rep Payee model. An economic analysis will be conducted to model the impact of the intervention as compared with standard of care on quality adjusted life years as well as new infections averted. This approach is innovative because it offers a structural intervention to improve adherence by addressing the effects of economic insecurity, requires low financial investment, and can be layered with existing clinical services. Further, it is highly scalable as it builds on a current policy in practice within the Social Security system.

NCT ID: NCT03554408 Recruiting - Clinical trials for Human Immunodeficiency Virus

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Start date: June 2018
Phase: Phase 1
Study type: Interventional

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.